Inhibition of dipeptidyl-peptidase 4 induces upregulation of the late cornified envelope cluster in keratinocytes

[1]  V. A. Jones,et al.  The role of Dipeptidyl Peptidase‐4 in cutaneous disease , 2020, Experimental dermatology.

[2]  M. Lynch,et al.  Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients with Diabetes: A Double-Blind Randomized Controlled Trial , 2019, Dermatology.

[3]  J. Ilonen,et al.  Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid. , 2019, Acta dermato-venereologica.

[4]  K. Kridin,et al.  Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. , 2019, Autoimmunity reviews.

[5]  K. Amber,et al.  Digital Quantification of Epidermal Protein Expression in Paraffin-Embedded Tissue Using Immunohistochemistry. , 2019, Methods in molecular biology.

[6]  Eun Woo Son,et al.  iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data , 2018, BMC Bioinformatics.

[7]  M. Khamaisi,et al.  Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study , 2018, Immunologic research.

[8]  Steven Xijin Ge,et al.  iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data , 2017, BMC Bioinformatics.

[9]  James T. Elder,et al.  Psoriasis-Associated Late Cornified Envelope (LCE) Proteins Have Antibacterial Activity. , 2017, The Journal of investigative dermatology.

[10]  H. Shimizu,et al.  Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid. , 2016, The Journal of investigative dermatology.

[11]  H. Shimizu,et al.  Autoantibody profile differentiates between inflammatory and non-inflammatory bullous pemphigoid , 2016 .

[12]  F. Kersten,et al.  Late cornified envelope (LCE) proteins: distinct expression patterns of LCE2 and LCE3 members suggest nonredundant roles in human epidermis and other epithelia , 2016, The British journal of dermatology.

[13]  K. Green,et al.  In Vitro Model of the Epidermis: Connecting Protein Function to 3D Structure. , 2016, Methods in enzymology.

[14]  S. Schneeweiss,et al.  Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study , 2014, Annals of the rheumatic diseases.

[15]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[16]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[17]  P. van Erp,et al.  CD26/dipeptidyl‐peptidase IV in psoriatic skin: upregulation and topographical changes , 2008, The British journal of dermatology.

[18]  M. Seyger,et al.  Distribution of dipeptidyl-peptidase IV on keratinocytes in the margin zone of a psoriatic lesion: a comparison with hyperproliferation and aberrant differentiation markers , 2008, Archives of Dermatological Research.

[19]  Thomas Lengauer,et al.  Improved scoring of functional groups from gene expression data by decorrelating GO graph structure , 2006, Bioinform..

[20]  H. Gollnick,et al.  DNA synthesis in cultured human keratinocytes and HaCaT keratinocytes is reduced by specific inhibition of dipeptidyl peptidase IV (CD26) enzymatic activity. , 2000, Advances in Experimental Medicine and Biology.

[21]  U. Lendeckel,et al.  Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). , 1999, International journal of molecular medicine.

[22]  P. Savoia,et al.  Effects of topical calcipotriol on the expression of adhesion molecules in psoriasis , 1998, Journal of cutaneous pathology.

[23]  P. Quaglino,et al.  Keratinocytes express dipeptidyl‐peptidase IV (CD26) in benign and malignant skin diseases , 1996, The British journal of dermatology.